Genovate Biotechnology Co., Ltd.

4130

TW0004130000

Pharmaceuticals

End-of-day quote Taipei Exchange Other stock markets 06:00:00 2024-04-25 pm EDT			5-day change	1st Jan Change
24.05 ^TWD	-0.21%		+1.05%	-9.59%

Mar. 28	Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	CI
2023	Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	CI

Genovate Biotechnology Co., Ltd. Announces Members of the Company's 5th Remuneration Committee

August 07, 2023 at 05:32 am EDT

Genovate Biotechnology Co., Ltd. announced members of the Company's 5th remuneration Committee. Name of the previous position holder: Lee,Shih-Jen, Liu,Ke-Yi. Resume of the previous position holder: Lee, Shih-Jen/TAHO Pharmaceuticals Ltd.,Chairman; Liu, Ke-Yi/BDO Taiwan Joint Venture Accountant.

Name of the new position holder: Lee,Shih-Jen-BLiu,Ke-Yi-BChang,Chin-Ming. Resume of the new position holder: Lee,Shih-Jen/TAHO Pharmaceuticals Ltd.,Chairman; Liu, Ke-Yi/BDO Taiwan Joint Venture Accountant; Chang,Chin-Ming/TaiMed Biologics Inc.,CEO. Effective date of the new member: August 7, 2023.

Latest news about Genovate Biotechnology Co., Ltd.

Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 28	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10	CI
Genovate Biotechnology Co., Ltd. Announces Members of the Company's 5th Remuneration Committee	23-08-07	CI
Genovate Biotechnology Co., Ltd. Announces Cash Dividend, Payable August 7, 2023	23-06-15	CI
Genovate Biotechnology Co., Ltd. Approves Election of Directors	23-05-29	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-15	CI
Genovate Biotechnology Co., Ltd. and CSPC Pharmaceutical Group Limited Sign the Agreement on Technology Licensing and Co-Development of DBPR108 in Mainland China	23-04-28	CI
Genovate Biotechnology Co., Ltd. Announces Resignation of Chen, Tehfang as Audit Committee Member and Convener of the Remuneration Committee, Effective April 10, 2023	23-04-06	CI
Genovate Biotechnology Co., Ltd. Announces Resignation of Chen, Tehfang as Independent Director, Effective April 10, 2023	23-04-06	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-25	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-25	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2022	22-11-09	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2022	22-08-11	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022	22-05-13	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2021	22-03-28	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2021	21-11-11	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2021	21-08-13	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2021	21-05-13	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Full Year Ended December 31, 2020	21-03-24	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Third Quarter Ended September 30, 2020	20-11-12	CI
Genovate Biotech Announces the Start of Its Clinical Trial (NCT04446416) for the Combination of FUS Plus Bevacizumab Therapy	20-09-11	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the Second Quarter Ended June 30, 2020	20-08-11	CI
Genovate Biotechnology Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2020	20-05-13	CI

Chart Genovate Biotechnology Co., Ltd.

Duration

Period

More charts

Company Profile

Genovate Biotechnology Co., LTD. is a Taiwan-based company principally engaged in the research, development, manufacture and sales of pharmaceutical preparations, drug substances and intermediates. The Company's products include nervous system drugs, digestive system drugs, analgesic and anti-inflammatory drugs, urogenital system drugs, antimicrobial drugs, cardiovascular system drugs, acne drugs, antineoplastic drugs and anti-diabetic drugs, as well as healthcare food and cosmetics. The Company is also engaged in the provision of clinical experimental testing services and technology export services. The Company distributes its products mainly within domestic market.

Sector

Pharmaceuticals

Calendar

2024-05-08 - Q1 2024 Earnings Release (Projected)

More about the company

Income Statement Evolution

More financial data

Sector Other Pharmaceuticals

	1st Jan change	Capi.
GENOVATE BIOTECHNOLOGY CO., LTD.	-9.59%	80.64M
ELI LILLY AND COMPANY	+25.83%	661B
NOVO NORDISK A/S	+26.80%	566B
JOHNSON & JOHNSON	-6.76%	352B
MERCK & CO., INC.	+20.34%	332B
ABBVIE INC.	+3.00%	283B
ASTRAZENECA PLC	+14.51%	231B
NOVARTIS AG	+4.78%	200B
ROCHE HOLDING AG	-9.37%	195B
AMGEN INC.	-6.26%	145B